Evidence map›Paper›PMID 29441497›Full record

ArticlePharmacoEconomics - open2017

Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II-III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial.

Abualbishr Alshreef, Allan J Wailoo, Steven R Brown, James P Tiernan, Angus J M Watson, Katie Biggs, Mike Bradburn, Daniel Hind

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PharmacoEconomics - open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04675177 (Sclerotherapy With Polidocanol Foam Versus Hemorrhoidal Artery Ligation With Recto Anal Repair in the Treatment of Second and Third-grade Hemorrhoidal Disease), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04675177 phase2 / phase3completednot on this mapstarted 2019, after this paper: background citation

Sclerotherapy With Polidocanol Foam Versus Hemorrhoidal Artery Ligation With Recto Anal Repair in the Treatment of Second and Third-grade Hemorrhoidal Disease: a Prospective Study

TypeinterventionalSponsorUniversidade do PortoRan2019 to 2020Enrolled45ConditionsHemorrhoidsArmsPolidocanol foam sclerotherapy, Doppler-guided hemorrhoidal artery ligation
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Abualbishr AlshreefHealth Economics and Decision Science, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. a.o.alshreef@sheffield.ac.uk.ORCID http://orcid.org/0000-0003-2737-1365
Allan J WailooHealth Economics and Decision Science, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.
Steven R BrownSheffield Teaching Hospitals, Sheffield, UK.
James P TiernanSt James's University Hospital, Leeds, UK.
Angus J M WatsonRaigmore Hospital, Inverness, UK.
Katie BiggsClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0003-4468-7417
Mike BradburnClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Daniel HindClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
University of Sheffield · GBRaigmore Hospital · GBSheffield Teaching Hospitals NHS Foundation Trust · GBSt James's University Hospital · GB

Funding

Health Technology Assessment Programme HTA 10/57/46
6 · The paper itself

Abstract

aimHaemorrhoids are a common condition, with nearly 30,000 procedures carried out in England in 2014/15, and result in a significant quality-of-life burden to patients and a financial burden to the healthcare system. This study examined the cost effectiveness of haemorrhoidal artery ligation (HAL) compared with rubber band ligation (RBL) in the treatment of grade II-III haemorrhoids.

methodThis analyses used data from the HubBLe study, a multicentre, open-label, parallel group, randomised controlled trial conducted in 17 acute UK hospitals between September 2012 and August 2015. A full economic evaluation, including long-term cost effectiveness, was conducted from the UK National Health Service (NHS) perspective. Main outcomes included healthcare costs, quality-adjusted life-years (QALYs) and recurrence. Cost-effectiveness results were presented in terms of incremental cost per QALY gained and cost per recurrence avoided. Extrapolation analysis for 3 years beyond the trial follow-up, two subgroup analyses (by grade of haemorrhoids and recurrence following RBL at baseline), and various sensitivity analyses were undertaken.

resultsIn the primary base-case within-trial analysis, the incremental total mean cost per patient for HAL compared with RBL was £1027 (95% confidence interval [CI] £782-£1272, p < 0.001). The incremental QALYs were 0.01 QALYs (95% CI -0.02 to 0.04, p = 0.49). This generated an incremental cost-effectiveness ratio (ICER) of £104,427 per QALY. In the extrapolation analysis, the estimated probabilistic ICER was £21,798 per QALY. Results from all subgroup and sensitivity analyses did not materially change the base-case result.

conclusionsUnder all assessed scenarios, the HAL procedure was not cost effective compared with RBL for the treatment of grade II-III haemorrhoids at a cost-effectiveness threshold of £20,000 per QALY; therefore, economically, its use in the NHS should be questioned.

Indexed as

Electronic Supplementary MaterialNational Health ServiceProbabilistic Sensitivity AnalysisRubber Band LigationSeemingly Unrelated Regression

Identifiers

PMID29441497
PMCPMC5691841
OpenAlexW2609646964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.